title: The IL-1beta system in epilepsy-associated malformations of cortical development.
abstract: Focal cortical dysplasia (FCD) and glioneuronal tumors (GNT) are recognized causes of chronic intractable epilepsy. The cellular mechanism(s) underlying their epileptogenicity remain largely unknown. Compelling evidence in experimental models of seizures indicates an important role of interleukin (IL)-1beta in the mechanisms of hyperexcitability leading to the occurrence of seizures. We immunocytochemically investigated the brain expression and cellular distribution pattern of IL-1beta, IL-1 receptor (IL-1R) types I and II and IL-1R antagonist (IL-1Ra) in FCD and GNT specimens, and we correlate these parameters with the clinical history of epilepsy in patients with medically intractable seizures. In normal control cortex, and in perilesional regions with histologically normal cortex, IL-1beta, IL-1Rs and IL-1Ra expression was undetectable. In all FCD and GNT specimens, IL-1beta and its signalling receptor IL-1RI were highly expressed by more than 30% of neurons and glia whereas the decoy receptor IL-RII and IL-Ra were expressed to a lesser extent by approximately 10% and 20% of cells, respectively. These findings show a high expression of IL-1beta and its functional receptor (IL-1RI) in FCD and GNT specimens together with a relative paucity of mechanisms (IL-1RII and IL-1Ra) apt to inactivate IL-1beta actions. Moreover, the number of IL-1beta- and IL-1RI-positive neurons was positively correlated with the frequency of seizures, whereas the number of IL-1Ra-positive neurons and astroglial cells was negatively correlated with the duration of epilepsy prior to surgery. The expression of IL-1beta family members in these developmental lesions may contribute to their intrinsic and high epileptogenicity, thus possibly representing a novel target for antiepileptic strategies.
authors.affiliation: Department of Neuroscience, Laboratory of Exp Neurology, Mario Negri Institute for Pharmacological Research, Milano, Italy.
authors.forename: T
authors.initials: T
authors.lastname: Ravizza
authors.forename: K
authors.initials: K
authors.lastname: Boer
authors.forename: S
authors.initials: S
authors.lastname: Redeker
authors.forename: W G M
authors.initials: WG
authors.lastname: Spliet
authors.forename: P C
authors.initials: PC
authors.lastname: van Rijen
authors.forename: D
authors.initials: D
authors.lastname: Troost
authors.forename: A
authors.initials: A
authors.lastname: Vezzani
authors.forename: E
authors.initials: E
authors.lastname: Aronica
mesh_terms: D000293:Adolescent; D000328:Adult; D001253:Astrocytes / Q000378:metabolism; D001932:Brain Neoplasms / Q000473:pathology; D002452:Cell Count; D002540:Cerebral Cortex / Q000002:abnormalities* / Q000254:growth & development; D002648:Child; D002675:Child, Preschool; D004827:Epilepsy / Q000150:complications* / Q000503:physiopathology* / Q000601:surgery; D005260:Female; D005910:Glioma / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D066298:In Vitro Techniques; D007375:Interleukin-1 / Q000502:physiology*; D008297:Male; D017628:Microglia / Q000378:metabolism; D009457:Neuroglia / Q000378:metabolism; D009474:Neurons / Q000378:metabolism; D019635:Neurosurgical Procedures; D009836:Oligodendroglia / Q000378:metabolism; D017472:Receptors, Interleukin-1 / Q000235:genetics
chemical_list: D007375:Interleukin-1; D017472:Receptors, Interleukin-1